Evolution of overall survival and receipt of new therapies by subtype among 20 446 metastatic breast cancer patients in the 2008-2017 ESME cohort-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Evolution of overall survival and receipt of new therapies by subtype among 20 446 metastatic breast cancer patients in the 2008-2017 ESME cohort

Published:2021-06 Issue:3 Volume:6 Page:100114
ISSN:2059-7029
Container-title:ESMO Open
language:en
Short-container-title:ESMO Open

Author:

Grinda T.,Antoine A.,Jacot W.,Blaye C.,Cottu P.-H.,Diéras V.,Dalenc F.,Gonçalves A.,Debled M.,Patsouris A.,Mouret-Reynier M.-A.,Mailliez A.,Clatot F.,Levy C.,Ferrero J.-M.,Desmoulins I.,Uwer L.,Petit T.,Jouannaud C.,Lacroix-Triki M.,Deluche E.,Robain M.,Courtinard C.,Bachelot T.,Brain E.,Pérol D.,Delaloge S.

Funder

Roche

Pfizer Ltd

Fujita Hoken Eisei Daigaku

AstraZeneca France

MSD

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference41 articles.

1. Cancer incidence and mortality patterns in Europe: estimates for 40 countries and 25 major cancers in 2018;Ferlay;Eur J Cancer.,2018

2. Global analysis of advanced/metastatic breast cancer: decade report (2005-2015);Cardoso;Breast.,2018

3. Molecular portraits of human breast tumours;Perou;Nature.,2000

4. Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study;Swain;Lancet Oncol.,2020

5. Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial;Di;Lancet Oncol.,2017

Cited by 66 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Observational Study of Men and Women with Breast Cancer in Terms of Overall Survival;Cancers;2024-09-01

2. The role of locoregional surgery in de novo stage IV breast cancer: A meta-analysis of randomized controlled trials;Cancer Treatment Reviews;2024-09

3. Transforming breast cancer management with real-world data and artificial intelligence;ESMO Real World Data and Digital Oncology;2024-09

4. Facilitating patient-oncologist communication in advanced treatment-resistant cancer: development and feasibility testing of a question prompt list;Pilot and Feasibility Studies;2024-08-28

5. Trends in HR+ metastatic breast cancer survival before and after CDK4/6 inhibitor introduction in the United States: a SEER registry analysis of patients with HER2− and HER2+ metastatic breast cancer;Breast Cancer Research and Treatment;2024-08-23

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3